Arcutis Biotherapeutics

#4028

Rank

$2.82B

Marketcap

United States

Country

Leadership team

Mr. Todd Franklin Watanabe M.A. (Pres, CEO & Director)

Dr. Bhaskar Chaudhuri Ph.D. (Co-Founder & Independent Director)

Mr. Scott L. Burrows (CFO & Principal Accounting Officer)

Products/ Services

Biopharma, Biotechnology, Health Diagnostics, Pharmaceutical, Therapeutics

Number of Employees

100 - 500

Headquarters

Westlake Village, California, United States

Established

2016

Company Registration

SEC CIK number: 0001787306

Revenue

500K - 2M

Traded as

ARQT

Social Media

URL

https://www.arcutis.com

Overview

Location

Recognition and Award

References

Summary

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

History

Arcutis was founded in 2018 with a single mission—to develop best-in-class treatments for skin diseases that have a significant unmet medical need. Through the years, the company has acquired numerous assets, completed multiple clinical trials, and gained approval of their lead asset, Roflumilast Ointment, for the treatment of plaque psoriasis in adults in the US.

Mission

Our mission is to help people suffering from serious skin diseases by developing and commercializing therapies that target immuno-dermatology, a rapidly growing specialty field in dermatology.

Vision

Our vision is to be the global leader in developing and commercializing high-quality, best-in-class treatments for people suffering from serious skin diseases.

Key Team

Dr. David W. Osborne Ph.D. (Chief Technical Officer)

Dr. Patrick E. Burnett M.D., Ph.D. (Sr. VP & Chief Medical Officer)

Mr. Matthew Richard Moore (Sr. VP & Chief Bus. Officer)

Ms. Patricia A. Turney (Sr. VP of Operations)

Mr. Eric McIntyre (Head of Investor Relations)

Ms. Courtney Barton (VP and Chief Compliance Officer & Privacy Officer)

Mr. Masaru Matsuda Esq., J.D. (Sr. VP, Gen. Counsel & Corp. Sec.)

Recognition and Awards

Arcutis was the winner of the 2019 BioPharma Breakthrough Award from Frost & Sullivan. The company was also recognized as one of the Cantech Investment Awards in 2019 and 2020.